Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

This study has been completed.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: October 12, 2011
Last updated: April 11, 2016
Last verified: March 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2015
  Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)